Everight Diagnostics
Engagement Planner · Everight × LabAssure
Abuja, Nigeria · Genomics Center of Excellence

Genomics Laboratory
Build & Commissioning Planner

A single working surface to align both teams — organised by lab zone, switchable into phase and pre/analytical/post lenses. Built to close the in-house outsourcing gap, stand up an ISO 15189 facility, and scale toward a pan-African reference lab.

ISO 15189 — Day 1 thread NAFDAC MLSCN NBMA (BSL-2) WHO Biosafety 4th ed · CAP-aligned
9
Functional Zones
Phlebotomy → discard, unidirectional flow, no backtracking
12–18mo
Build Horizon
Interim referral bridge runs the entire build
~$1.3M+
Indicative Phase I CapEx
Equipment envelope before fit-out & IT
4
Regulatory Bodies
MLSCN · NAFDAC · NBMA · ISO 15189 accreditation
Lens
Zone view — tap any card to expand requirements, equipment & biosafety
01 / ZONES

The Nine-Zone Laboratory

Unidirectional sample flow governed by ISO 15189, WHO Biosafety Manual (4th ed.) and Nigerian FMOH guidelines. PCR work is split across three mandatory sub-rooms with no material backtracking. Tap a zone for the build detail.

01 / PHASES

Phased Build Sequence

Same zones, sequenced by capability go-live. Phase I stands up clinical genetics + molecular + cytogenetics + Sanger; Phase II adds NGS, microarray and the bioinformatics HPC. ISO 15189 and the interim referral bridge run across both.

Pre-analytical
Collection · accession · prep

Everything before the test runs — where most errors originate and where the LIS chain of custody is set.

A · PhlebotomyB · AccessionC1 · Reagent PrepC2 · Template Prep
Analytical
Amplify · culture · sequence

The instruments earning revenue. Contained, power-protected, environment-controlled.

C3 · AmplificationD · CytogeneticsE · SangerF · NGS / Array
Post-analytical
Analyse · report · store · discard

The half of an NGS lab that is software, storage and interpretation — plus storage & compliant waste.

G · BioinformaticsH · ULT StorageI · Biomedical Waste

The zone cards below are now grouped by workflow stage. Tap any to expand.

02 / STRUCTURE

Partnership Models

Everight's email asked directly for "partnership models." Rather than a single consulting engagement, here are four structures along a spectrum of shared risk and reward — Everight indicates which fits the vision.

Model A

Advisory Consulting

Fixed-fee · milestone-based
  • LabAssure designs, equips, validates & trains to handover
  • Everight owns the asset and all future revenue
  • Lowest LabAssure risk, fastest to contract
Fits if: Everight wants full ownership and is confident running ops post-handover.
Model B

Build + Technical Retainer

Project fee + monthly advisory
  • Consulting build, then 12–24mo ongoing technical mentorship
  • Remote VPN support, EQA oversight, SOP upkeep
  • De-risks the fragile first year of operation
Fits if: Everight wants ownership but a safety net while capability matures.
Best strategic fit
Model C

Revenue-Share Partnership

Reduced upfront + % of test revenue
  • Lower entry fee; LabAssure shares test-volume revenue for a fixed term
  • Interests aligned — both sides win on throughput & quality
  • Natural home for the interim referral bridge economics
Fits if: Everight wants to conserve capital and treat LabAssure as a long-term stakeholder.
Model D

Joint Venture / Co-CoE

Equity / co-owned reference lab
  • Jointly owned center of excellence; shared governance
  • Platform for the pan-African reference-lab ambition
  • Deepest commitment, highest combined upside
Fits if: the long game is a regional CoE, not a single Abuja facility.
03 / ECONOMICS

The Financial Narrative

The engagement fee should be read against what outsourcing already costs Everight today — not in isolation. The figures below are an indicative framing model to be replaced with Everight's actual referral volumes.

Today — Value Leaving Nigeria

$0.9–1.6M/yr
Indicative annual spend on tests currently sent abroad (illustrative — pending Everight's referral data).
  • Cytogenetics / karyotyping outsourced
  • PGT for partner fertility centers outsourced
  • Oncology molecular panels outsourced
  • NGS & CMA outsourced
  • Turnaround time & FX cost + margin lost

In-House — Captured + New Demand

Yr 1 break-in
Recaptured outsourced volume + new clinician/fertility/hospital demand routed through the network.
  • Recapture outsourced margin retained locally
  • Faster TAT → higher referral volume
  • New test menu (PGT, oncology NGS) new lines
  • Referral-lab income from peer labs upside
  • Brand: first-mover genomics CoE strategic
Payment milestones tie to deliverable milestones (design sign-off · equipment commissioning · validation pass · ISO readiness · go-live), not elapsed time. Final figures to be modelled jointly from Everight's outsourcing ledger.
03b / CAPEX

Indicative Equipment Envelope

Reconciled from the draft deck. Bioinformatics infrastructure is added explicitly — for an NGS lab it is roughly half the operation and was missing from the draft.

Capability / ZoneIndicative CapExPhaseNote
Molecular Testing (Zone C)~$100KPhase IReal-time PCR, extraction, BSC
Cytogenetics (Zone D)$125–400KPhase I$125–150K manual · $350–400K automated karyotyping
Sanger Sequencing (Zone E)~$150KPhase ICapillary electrophoresis (SeqStudio / 3500xL)
Chromosomal Microarray (Zone F)~$250KPhase IIScanner + controlled-temp room
Next-Gen Sequencing (Zone F)$250K–$2MPhase IIPlatform-dependent; NAS RAID ≥200TB included
Bioinformatics & HPC (Zone G)$80–250KPhase IIHPC rack, ≥64GB workstations, pipelines, variant DB, dual UPS
ULT Storage & Cold Chain (Zone H)$60–120KPhase I2× −80°C (redundant), LN₂, monitored alarms
04 / BRIDGE

Interim Sample-Referral Model

Everight keeps losing revenue abroad for 12–18 months unless there's a transition. During the build, Everight routes samples to LabAssure instead — early revenue for LabAssure, and Everight's team learns the workflows before the lab even opens.

01
Redirect outsourcing
Samples currently sent to scattered foreign labs are consolidated to LabAssure under one SLA & chain of custody.
02
Shadow the workflow
Everight scientists observe accessioning, wet-lab & reporting remotely — building familiarity ahead of go-live.
03
Co-report & validate
As zones commission, tests migrate in-house under dual-report validation against LabAssure as reference.
04
Full handover
Referral tapers to overflow / esoteric tests only. Everight runs the menu; LabAssure stays a back-stop.
04b / PROCUREMENT

Equipment Order Process

A 10-step path from finalising the equipment list to a validated, staff-operable instrument — with responsibility split between Everight, LabAssure and the vendor at each step. Customs clearance is the most common slip point for imported instruments into Nigeria, so it gets its own line.

#ActivityResponsibilityTimeline
01Finalise equipment list with LabAssureEveright LabAssureMonth 1
02Issue RFQs to vendorsEveright procurementMonth 1–2
03Evaluate bids & negotiateEveright LabAssureMonth 2
04Issue Purchase OrdersEverightMonth 2–3
05Vendor ships equipmentVendorMonth 3–5
06Customs clearanceClearing agentMonth 5–6
07Delivery & inspectionEveright Vendor engineerMonth 6
08Installation & commissioningVendor LabAssure oversightMonth 6–7
09Performance Qualification (PQ)Vendor LabAssureMonth 7
10Method validation by lab staffLab staff LabAssure guidanceMonth 7–8
04c / SCHEDULE

High-Level Project Timeline

The full build mapped across the first 12 months, with Phase II expansion and ISO 15189 accreditation shown as the longer horizon. Hatched bars denote Phase II / months 18+.

Workstream
M1M2M3M4M5M6M7M8M9M10M11M12
Pre-construction & regulatory Construction & equipment Validation, launch & ops Phase II / Mo 18+
05 / COMPLIANCE

Nigeria Licensing & Regulatory Roadmap

ISO 15189 is treated as a thread woven from Day 1 — document framework, SOPs and QC built in from requirements-gathering, not bolted on at month 9. The Nigerian statutory bodies are mapped below with what each one actually requires, drawn from current MLSCN, NAFDAC and NBMA guidance.

MLSCN
Medical Lab Science Council of Nigeria
Facility approval & licensing under Act 11 of 2003. Mandatory before operating — the lab must be headed by a resident Medical Laboratory Scientist.
▸ Earliest — pre-fit-out
NAFDAC
Food, Drug Administration & Control
IVD / reagent & kit registration under the Medical Devices & IVD Regulations (2024–25). Risk-classed I–IV; certificates valid 5 years via the NAPAMS portal.
▸ Procurement phase
ISO 15189
Medical laboratory QMS accreditation
The quality spine. Built from Day 1; formal accreditation assessment targeted ~Months 18–24 once the QMS has an operating record.
▸ Day 1 → accredit Mo 18–24
NBMA
National Biosafety Mgmt Agency
Required only if the lab handles GMOs, genome editing or synthetic biology (NBMA Act 2015, amended 2019). Routine clinical genetics sits outside its core scope — confirm applicability early.
▸ Confirm scope upfront
What MLSCN approval actually requires

From the MLSCN Guidelines on Medical Laboratory Approval and pre-registration checklist (105 items / 208 points). The essentials to assemble:

Documentation
  • Completed MLSCN application form + letter of intent from Director / Proprietor
  • CAC business registration certificate (or enabling Act for public bodies)
  • Laboratory Information System (LIS) in place at inspection
Personnel
  • Resident Medical Laboratory Scientist with current practising licence
  • ≥5 years post-NYSC experience; must be a full-time employee
  • Registered scientists proportional to workload, present during all operating hours
NAFDAC IVD pathway
  • ISO 13485 QMS cert + CE / FDA 510(k) or Free Sale Certificate from origin
  • Risk classification I–IV; analytical & clinical performance data
  • Power of Attorney for foreign manufacturers; register via NAPAMS portal
The resident MLS director is the long-lead item — identify and contract this person before fit-out, since MLSCN approval, NAFDAC submissions and ISO readiness all depend on having a licensed scientist of record in place.
06 / CAPABILITY

Training Academy — Competency Tracks

The client emphasised training across six areas; a two-week block is disproportionate. Structured as role-based tracks with competency sign-off, running through the build and continuing post go-live.

Track 1 · Wet-lab

Molecular & Cytogenetics

  • Extraction, PCR, real-time PCR
  • Karyotyping, FISH, cell culture
  • Competency sign-off per assay
Track 2 · Sequencing

Sanger & NGS

  • Sanger run & troubleshooting
  • NGS library prep → run → QC
  • Hands-on under mentorship
Track 3 · Dry-lab & QA

Bioinformatics · Interpretation · EQA / CPD

  • Pipelines, variant calling & interpretation
  • Reporting standards & sign-out
  • EQA enrolment + ongoing CPD program
07 / HORIZON

Beyond Phase I — The Pan-African Story

Everight's ambition to serve the wider continent deserves a response at the same strategic altitude. This isn't a single Abuja lab — it's the seed of a regional reference center.

Regional Reference Lab
Position Abuja as the West-African esoteric-testing hub — peer labs across the region refer in, reversing the outbound-sample flow continentally.
Collaborative Research
African-genome representation in variant databases, partnerships with universities & consortia, publishable population data.
Public-Health Genomics
Pathogen surveillance, hereditary disease screening & oncology programs that scale from clinical service into population health.